Product Information
CIPROFLOXACIN HCL 250 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0751 per EA under NDC 16571041110. Its NADAC has been published 633 times since Nov 28, 2013.
FDA first approved this application on Sep 10, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571041110
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CIPROFLOXACIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076639FDA Approved
9/10/2004
TE Code
AB
On Market Since
9/10/2004
Pharmacological Classes
Price Statistics
The NADAC for CIPROFLOXACIN HCL 250 MG TAB has been published 633 times since Nov 28, 2013, and over the history we have for it it has declined 40.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0751 per EA |
|---|---|
| All-time high | $0.1749 (Jun 10, 2015) |
| All-time low | $0.0751 (Sep 23, 2026) |
| 52-week high | $0.0914 |
| 52-week low | $0.0751 |
| Median price | $0.1001 |
| Average price | $0.1094 |
| Largest weekly change | -21.4% (Apr 17, 2024) |
| Weeks tracked | 633 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ciprofloxacin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ciprofloxacin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Fluoroquinolone Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CIPROFLOXACIN HCL 250 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CIPROFLOXACIN HCL 250 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.0751 per EA (NDC 16571041110), effective Sep 30, 2026.
How has the price of CIPROFLOXACIN HCL 250 MG TAB changed over time?
Over the history we have for it, the NADAC for CIPROFLOXACIN HCL 250 MG TAB has declined 40.9%. It has been tracked across 633 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CIPROFLOXACIN HCL 250 MG TAB?
Since Nov 28, 2013, the NADAC for CIPROFLOXACIN HCL 250 MG TAB has ranged from a low of $0.0751 (Sep 23, 2026) to a high of $0.1749 (Jun 10, 2015), with a median of $0.1001 per EA.
Are there cheaper alternatives to CIPROFLOXACIN HCL 250 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of CIPROFLOXACIN HCL 250 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CIPROFLOXACIN HCL 250 MG TAB?
CIPROFLOXACIN HCL 250 MG TAB (NDC 16571041110) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.